Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telaprevir + peginterferon alfa-2a + ribavirin
- Development stage
- Discontinued
- Lead developer
- Vertex
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
**Telaprevir + peginterferon alfa-2a + ribavirin** is a triple combination antiviral regimen used in the treatment of chronic hepatitis C virus (HCV) infection, predominantly genotype 1, in adults. Telaprevir is an HCV NS3/4A protease inhibitor that blocks viral replication by inhibiting a critical viral enzyme[3]. Peginterferon alfa-2a is a long-acting form of recombinant interferon alpha, which stimulates the immune system to fight HCV[3]. Ribavirin is a nucleoside analogue antiviral that enhances the effect of interferon and helps suppress viral replication[3]. The combination was developed to increase sustained virologic response (SVR) rates compared to peginterferon/ribavirin dual therapy, though it has been supplanted by direct-acting antivirals with improved safety and efficacy profiles[6].
- Brand names
- Incivek
- Other names
- triple therapy for hepatitis CTPRtelaprevir-based triple therapy
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on telaprevir + peginterferon alfa-2a + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telaprevir + peginterferon alfa-2a + ribavirin.